Pharming underperforms past years Dutch exchanges

The past years Pharming lost a lot. Because of the losses of 57 percent over the past 12 months the share is one of the worst performing shares in the Netherlands. The average Dutch stock gained the past 5 year approximately 165 percent. Among the losers in the Netherlands over the same period are Espirite, Lavide and Kardan.

Returns Pharming versus Dutch stocks

Buy & hold Returns stock Pharming several periods, excluding dividend returns

Investors who invested in 2007 in the company's share now have a massive loss of 81 percent. over the past 90 days the stock made a loss of percent.

For this year Pharming's revenue will be around 164,19 million euros. This is according to the average of the analysts' estimates. This is hugely more than 2017's revenue of 135,13 million euros.

Historical revenues and results Pharming plus estimates 2018

The analysts expect for 2018 a net profit of 36 million euros. Most of the analysts anticipate on a profit per share of 5 cent. Based on this the price/earnings-ratio is 16,6.

For this year analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies equals a low 0,5 percent.

Most recent target prices around 2 euros

Stifel, Beleggers Belangen and Beursexpres recently provided recommendations for the stock.

Pharming's market capitalization is based on the number of outstanding shares around 482,2 million euros. The Pharming stock was the past 12 months quite volatile. Since last April the stock is 37 percent lower. This year the stock price moved between 1 and 2 euro. Since 2008 the stock price is almost 81 percent lower.

Historical stock prices Pharming2007-2018

At 12.07 the stock trades 2,21 percent lower at 0,83 euros.

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.